Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
1
© 2013 Paradigm Medical Communications, LLC
except where noted.
Hyponatremia
Obstacles and Opportunities for Clinical Pharmacists
Introduction of Case Study & The Pharmacist’s Role in Hyponatremia Management
The Pathophysiology of Hyponatremia
A Practical Approach to Hyponatremia Management: Conventional & Novel Therapies
Discussion and Q&A
Agenda
Hyponatremia: Signs, Symptoms, and Clinical Burden
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
2
Case StudyHyponatremia in SIADH
� An 80-year-old woman was referred to the clinic for management of chronic hyponatremia
� Patient’s daughter explained that her mother’s symptoms had been getting increasingly worse, including
� Weakness and feeling “shaky”
� Unsteady gait and falls
� Memory problems
� Poor response to fluid restriction and loop diuretics
1
Case StudyHistory
� Chronic systolic heart failure
� DVT
� HTN
� Anemia
� Severe pulmonary HTN
� GERD
� COPD
� Insomnia
� Anxiety
� Social history
� Widow
� No alcohol, cigarette, drug use
� Lives at home with daughter
� No known drug allergies
� Family history
� Both patients had CAD
� Mother died from breast cancer
in her 80s
2CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; DVT, deep venous thrombosis,
GERD, gastroesophageal reflux disease; HTN, hypertension.
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
3
Case StudyCurrent Medications
� Carvediol 25 mg bid
� Warfarin 5 mg qd
� Olmesartan 20 mg qd
� Rabeprazole 20 mg qd
� Tiotropium 18 µg inhaled qd
� Fluoxetine 10 mg qd
� Furosemide 20 mg qd
3
Case StudyPhysical Exam
� Pleasant, alert, and oriented
� BP 122/68 mm Hg, HR 72 bpm, RR 18, temp: 97.4°F
� HEENT: moist mucous membranes, EOMI
� Neck: supple, no JVD, no bruits
� Chest: good air entry, clear to auscultation, no rales
� Heart: S1, S2, RRR, no rub
� Abdomen: soft, nontender, normal bowel sounds
� Extremities: no edema
� Musculoskeletal: muscle strength 5/5 all extremities, sensory intact to light touch, DTRs equal in biceps and patella bilaterally
DTR, deep tendon reflex; EOMI, extraocular movements intact; HEENT, heart, eyes, ears, nose, and throat;
HR, heart rate; JVD, jugular venous distension; RR, respiratory rate; RRR, regular rate and rhythm. 4
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
4
Case StudyLaboratory Results
BUN, blood urea nitrogen; [Na+], serum sodium concentration; NT-proBNP, N-terminal prohormone of brain
natriuretic peptide; WNL, within normal limits. 5
2 wk prior to exam
Serum [Na+]: 121 mEq/L
Day of exam
Serum [Na+]: 128 mEq/L Creatinine: 1.1 mg/dL
Serum [K+]: 4.6 mEq/L Glucose: 78 mg/dL
Serum [Ca+]: 9.4 mEq/L Albumin: 4.5 g/dL
Uric acid: 3.6 mg/dL Liver function tests: WNL
BUN: 22 mg/dL NT-proBNP: 350 pg/mL
6 d after exam
Serum [Na+]: 121 mEq/L Urine osmolality: 254 mOsm/kg
Serum osmolality: 259 mOsm/kg
Many Roles of the Pharmacist
Monitor for hyponatremia development +
resolution
Consider a more pathophysiologic
approach to diagnosis and
treatment
Consider drug-related causes of
hyponatremia
Ensure appropriate monitoring for morbidities of hyponatremia
Ensure optimal management of hyponatremia
Participate in clinical decision
making
Participate in formulary decision making
and address cost-containment concerns
beyond acquisition costs
Educate clinicians on hyponatremia
Develop preventative hospital systems directed toward hyponatremia
6
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
5
The Pathophysiology of Hyponatremia
Learning Objective
� Summarize the pathophysiology of hyponatremia with an appreciation for the role of vasopressin
Hyponatremia: Incidence
� Common definition: serum sodium concentration ([Na+) ≤135 mEq/L, but cut-off values vary
� Typically occurs due to excess body water diluting serum sodium as a result of excess vasopressin / AVP/ ADH
� Most common electrolyte disorder seen in clinical practice1-3
� Occurs in up to 3.2 to 6.1 million persons annually4
� Up to 15% of hospitalized patients, 24.5% of ICU patients5,6
� ≈ 1 million annual hospitalizations with 1° or 2° discharge diagnosis of hyponatremia4
� Incidence increases with age7
AVP, arginine vasopressin; ADH, antidiuretic hormone; ICU, intensive care unit.
1. Ellison DH et al. N Engl J Med. 2007;356: 2064-2072. 2. Verbalis JG et al. Am J Med. 2007;120:S1-S21. 3. Upadhyay A et al. Am J Med.
2006;119(7A):S30-S35. 4. Boscoe A et al. Cost Eff Resour Alloc. 2006;4:10. 5. Baylis PH. Int J Biochem Cell Biol. 2003;35:1495-1499.
6. Cawley M. Ann Pharmacother. 2007;41(5):840-850. 7. Hawkins RC. Clinica Chimica Acta. 2003;337:169-172. 8
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
6
Hyponatremia: Underreported, Often Mismanaged
� Clinical lab values vsICD-9 codes 1999–2000
� 2632 cases of hyponatremia identified using lab data alone
� 66% did not have appropriate ICD-9 code� 94% of moderately hyponatremic
patients
� 87% of severely hyponatremic patients
� Review of 104 patients with serum [Na+] <125 mEq/L from 6-mo lab/chart data in large teaching hospital� 49% of diagnoses inconsistent
with clinical details
� 33% had “significant” management errors
Movig K et al. J Clin Epidemiol. 2003;56:530-535. 9
Reported cases of hyponatremia from databases represent
only 1/3 of cases
41
20
0
20
40
60
Management Errors Appropriate
Management
Mortality, %
Huda MS et al. Postgrad Med J. 2006;82:216-219.
Classification of Hyponatremia
Dilutional Hyponatremia
Total body water INCREASED
The most common type
SIADHHypothyroidismSecondary adrenal
insufficiency
Hypervolemic(edema)
Total body sodiumINCREASED
Heart failureCirrhosisNephrotic syndromeRenal failure
Depletional Hyponatremia
Total body water DECREASED
Hypovolemic
Total body sodium DECREASED
Diarrhea PancreatitisVomiting Diuretic useBurns Renal salt wastingTrauma Primary adrenal
insufficiency
Euvolemic(no edema)
Total body sodiumUNCHANGED
SIADH, syndrome of inappropriate antidiuretic hormone secretion.Cawley M. Ann Pharmacother. 2007;41(5):840-850. Cole CD et al. Neurosurg Focus. 2004;16(4):E9. 10
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
7
Etiologies of Hypo-osmolarHyponatremia
CNS, central nervous system.Cole CD et al. Neurosurg Focus. 2004;16(4):E9. Verbalis JG et al. Am J Med. 2007;120:S1-S21. 11
Hypervolemia
Heart failure
Cirrhosis
Nephrotic
syndrome
Anaphylaxis
Renal failure
Sepsis
Pregnancy
Euvolemia
SIADH
• Tumors
• CNS disorders
• Drug-induced
• Pulmonary diseases
• Other
Glucocorticoid deficiency
Hypothyroidism
Primary polydipsia
Hypovolemia
Thiazide diuretics
Cerebral salt wasting
Mineralocorticoid deficiency
Salt-wasting nephropathy
Bicarbonaturia, glucosuria,
ketonuria
Gastrointestinal losses
Third space losses
Sweat losses
Most often a complication of other illnesses in which excess water accumulates in the body at a higher rate than can be excreted
Receptor-Mediated Effects of Arginine Vasopressin (AVP)
� Plasma osmolality (Posm) is regulated by thirst and release of AVP
� Also known as antidiuretic hormone (ADH)
Receptor
subtype Site(s) of action Activation effects
V1a
� Vascular smooth muscle cells1
� Platelets1
� Lymphocytes and monocytes1
� Liver1
� Vasoconstriction, myocardial stimulation1
� Platelet aggregation1
� Cytokine release2
� Glycogenolysis1
V1b� Anterior pituitary1 � Release of ACTH1
and β-endorphin3
V2� Renal collecting duct1
� Renal free water absorption1
1. Verbalis JG. J Mol Endocrinol. 2002;29(1):1-9.
2. Loxley HD et al. Neuroendocrinology. 1993;57:801-814.
3. Kjaer A. Acta Endocrinol. 1993;129:489-496. 12
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
8
Pathophysiology of Hyponatremia
AQP2, aquaporin-2; cAMP, cyclic adenosine monophosphate; PKA, protein kinase A; V2, vasopressin-2.© Leiden University. From Dubois EA et al. Br J Clin Pharmacol. 2012;73(1):9-11.
� Increased AVP concentrations increase activity of V2 receptors in renal collecting ducts
� This activates synthesis of adenylate cyclase, cAMP, and PKA, enhancing expression of AQP2 channels
� AQP2 channels transport water molecules from collecting duct back into circulation, resulting in decreased Posm and reduced urine volume
� Na+ excretion continues, resulting in hyponatremia
13
Dysregulation of Normal AVP Response Complicates Many Disease States
SAH, subarachnoid hemorrhage; TBI, traumatic brain injury.
1. Greenberg H. 2011. Available at: www.medscape.org/viewarticle/753199_transcript. Accessed May 1, 2013. 2. Goldsmith SR.
Am J Cardiol. 2005;95(suppl):14B-23B. 3. Porcel A et al. Arch Intern Med. 2002;162:323-328. 4. Nair V et al. Am J Nephrol.
2007;27:184-190. 5. Tang WW et al. Am J Med. 1993;94(2):169-174. 6. Agha A et al. J Clin Endocrinol Metab. 2004;89:5987-5992.
7. Speedy DB et al. Med Sci Sports Exerc. 1999;31:809-815.
During extreme exercise (marathons + triathlons), up to 29% of athletes develop hyponatremia.7
14
Disease State
Prevalence of Hyponatremia in
Hospitalized Patients Mechanism
Heart failure (HF)1,2 ≈20% Neurohormonal activation
Cirrhosis3 35% Neurohormonal activation
Community-acquired pneumonia4 10%–28% SIADH ± reset osmostat
AIDS5 38% SIADH
Neurologic injury (TBI, SAH, infection, intracerebral hemorrhage, massive cerebral infarction, others)6
2.3%–36.6% SIADH, idiopathic
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
9
CNS, central nervous system; MAOIs, monoamine oxidase inhibitors; TCAs, tricyclic antidepressants;
SSRIs, selective serotonin reuptake inhibitors.
1. Adrogué HJ. Am J Nephrol. 2005;25:240-249. 2. Liamis G et al. Am J Kidney Dis. 2008;52(1):144-153.
3. Fourlanos S et al. Aust Prescr. 2003;26:114-117. 15
Hyponatremia: Risk Factors
Drugs� Antidepressants
(TCAs, SSRIs, MAOIs)1,2
� Antiepileptics1
� Antihypertensives3
� Antipsychotics1
� Anticancer agents1
� Diuretics1
� NSAIDS3
� Opiate derivatives1
� Proton-pump inhibitors3
Miscellaneous conditions� Adrenal insufficiency1
� Cirrhosis1
� CNS impairment1
� Heart failure1
� Low body weight2
� SIADH3
� Surgery or injury1
� Very old age1
� Very young age1
Mechanisms of Drug-Induced Hyponatremia
Antidepressants
Antipsychotics
Antiepileptics
Antineoplastic agents
Opiates
Antidiabetic drugs
Antiepileptics
Antineoplastic agents
NSAIDs
Thiazide diuretics/indapamide
Amiloride
Loop diuretics
↑↑↑↑ Effect of AVP at renal tubule level
Altered Na / H2O homeostasis
↑↑↑↑ Hypothalamic production of AVP
Liamis G et al. Am J Kidney Dis. 2008;52(1):144-153. 16
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
10
SSRI-Induced Hyponatremia
� 0.5%‒32% incidence1
� Most cases during first few weeks of therapy1
� Normal serum [Na+] usually achieved within 2 weeks following discontinuation of drug
� Risk factors
� Older age1,2
� Concomitant diuretic therapy1,2
� Low body weight2
� Baseline serum [Na+] <138 mEq/L2
171. Liamis G et al. Am J Kidney Dis. 2008;52(1):144-153. 2. Jacob S et al. Ann Pharmacother. 2006;40(9):1618-1622
Hyponatremia: Signs, Symptoms, and Clinical Burden
Learning Objective
� Identify the signs, symptoms, and clinical consequences of hyponatremia
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
11
Osteoporosis
and
fracturesHyponatremia
Consequences of Hyponatremia
Gait
disturbances
and falls
Neurologic
dysfunction and
decreased mental
function
Cerebral
edemaSeizures,
coma
Increased
mortality
risk
Increased
hospital
LOS
Increased
rate of ICU
admission
19
Hyponatremia & Neurologic Dysfunction
*The SF-12 is a subset of the SF-36 Health Survey and has been shown to reproduce at least 90% of the variance in PCS-36 and MCS-36 in both general and patient populations.
Advisory Committee Meeting of the Cardiovascular and Renal Drugs Division of the US Food and Drug Administration. June 25, 2008.
Available at: www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4373b1-05.pdf. Accessed March 15, 2013. 20
SF-12* Mental Component Summary (MCS)
Depression
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
12
Correction of Hyponatremia Improves Mental Function
Mean change in MCS score from baseline
� Statistically greater mean improvement observed with tolvaptan than with placebo
� Clinically meaningful improvement in mentalfunction
21Advisory Committee Meeting of the Cardiovascular and Renal Drugs Division of the US Food and Drug Administration. June 25, 2008.
Available at: www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4373b1-05.pdf. Accessed March 15, 2013.
5.3
4.7
5.95.4
1.6
0.2
1.92.4
Total Cirrhosis CHF SIADH
MCS
Tolvaptan
Placebo
*P<.05
**
Hyponatremia, Gait Instability,& Falls
� Case-control study of 122 patients with asymptomatic chronic hyponatremia ([Na+] 126 ± 5 mEq/L), 244 matched controls
� Hyponatremic patients more often admitted for falls than controls (21.3% vs 5.3%; P <.001)
� Frequency of falls the same—regardless of level of hyponatremia
� Gait instability significantly increased in patients with chronic hyponatremia
� Attention errors increased 1.2-fold (P=.001) in hyponatremic patients compared with normal controls
� Comparable to increase observed after moderate alcohol intake in healthy volunteers
Renneboog B et al. Am J Med. 2006;119:71.e1-8. 22
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
13
Reprinted from Renneboog B et al. Mild chronic hyponatremia is associated with falls, unsteadiness,
and attention deficits. Am J Med. 2006;119:71.e1-8. © 2006, with permission from Elsevier.
Gait stability assessed in 16 hyponatremic patients ([Na+] 124-130 mEq/L)� Patients asked to walk on pressure mat� Skew from midline of path measured as length of walk
Correction of Hyponatremia Stabilizes Gait
Gait instability significantly increased in hyponatremia Gait stability normalized
Correctionof hyponatremia
23
Hyponatremia & Fractures in Ambulatory Falls
� Case-control study of bone fractures after incidental fall1
� Patients presenting with falls and fractures had significantly higher incidence of hyponatremia (13.1%) than age-matched controls (3.9%)
� Hyponatremia drug-induced in 53% (36% diuretics, 17% SSRI),
� Hyponatremia due to SIADH in 37%
• Hyponatremia significantly associated with fracture (P=.01) 2
� Independent of age and gender2
� Even mild chronic hyponatremia increases fracture risk3
1. Gankam Kengne FG et al. Q J Med. 2008;101:583-588. 2. Sandhu HS et al. Int Urol Nephrol. 2009;41:733-737.
3. Hoorn EJ et al. J Bone Miner Res.. 2011;26(8):1822-1828. 4. Verbalis JG et al. J Bone Miner Res. 2010;25(3):554-563. 24
Bone quality should be assessed in all patients with chronic hyponatremia4
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
14
� 1-y study of 4123 patients (≥65 y) admitted to community hospital; 3.5% had admission serum [Na+]<130 mEq/L1
� Mortality increased as serum [Na+] decreased
� Admission hyponatremia significant predictor of in-hospital mortality (RR, 1.95; P<.006)
� Even mild hyponatremia is associated with increased in-hospital mortality2
� Mild hyponatremia also associated with increased mortality in an ambulatory setting3
Hyponatremia is an Independent Risk Factor for In-Hospital Mortality
8
15
19
0
5
10
15
20
>129
mEq/L
120-129
mEq/L
<120
mEq/L
Mortality, %1
RR, relative risk.1. Terzian C et al. J Gen Intern Med. 1994;9:89-91. 2. Waikar SS et al. Am J Med. 2009;122:857-865.
3. Gankam-Kengne F et al. Kidney Int. 2013;83(4):700-706. 25
Impact of Hyponatremia on Selected Hospital Outcomes
HN Cohort Non-HN Cohort P-Value
LOS, d 8.8 ± 10.3 7.7 ± 8.5 < .001
Hospital Admission Costs $15,281 ± $24,054 $13,439 ± $22,198 < .001
ICU LOS, d 5.5 ± 7.9 4.9 ± 7.1 < .001
ICU Costs $8525 ± $13,342 $7597 ± $12,695 < .001
Increased Chance of Hospital
Readmission 30 d Postdischarge15% < .0001
261. Amin A et al. J Hosp Med. 2012;7:634–639
� 558,815 hyponatremic (HN) patients selected from Premier Hospital Database from 1/1/07 to 3/31/10, matched to 558,815 non-HN control cohort using propensity score matching
� Differences in healthcare resource utilization, costs, and hospital readmissions between cohorts calculated using bivariate and multivariate statistics
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
15
Symptoms Correlate with Severity & Rate of Decline in Serum [Na+]1
� Asymptomatic presentation is common2
� May present with mild, nonspecific symptoms1
� Degree of symptomatology is surrogate for duration of hyponatremia1
� Symptoms from underlying disease process is also common1
Symptom
Respiratory arrest
Coma
Seizures
Delirium
Restlessness
Lethargy
Headache
Fatigue
Confusion
Nausea + vomiting
Asymptomatic
Increasing severity of
hyponatremia and rate of
[Na+] decline
271. Bagshaw SM et al. J Can Anesth.2009;56:151-167. 2. Ghali K. Cardiology. 2008;111:147-157.
Acute Versus Chronic Hyponatremia
� Life-threatening: usually ACUTE
� Symptomatic but less impaired: usually CHRONIC
28
Acute (≤48 h) Chronic (>48 h)
Symptoms include:
• Cerebral edema
• Seizures
• Increased mortality risk
Symptoms include:
• Nausea/vomiting
• Confusion or personality changes
• Neurologic dysfunction
• Gait disturbances
• Seizures (with very low serum [Na+] levels)
Rapid correction reverses cerebral
edema without sequelae
Rapid correction may cause brain dehydration
and osmotic demyelination syndrome (ODS)
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
16
H2O moves into brain along osmotic gradients,
causing symptomatic cerebral edema
Extracellular Na+
decreases byNa+ loss or H2O gain
29
Hypotonic state
Compensatory mechanism begins
Water gain
Cerebral swelling
When brain swelling >8%, it exceeds
skull capacity
Acute hyponatremia(≤48 h)
Chronic hyponatremia
(>48 h)
Gullans SR et al. Annu Rev Med. 1993;44:289-301. Verbalis JG. Endocrinol Nutr. 2010;57(Suppl 2):30-40.
Loss of electrolytes and osmolytes
decreases brain solute content
Brain edema is virtually absent
Herniation and death
Pathophysiology Adaptation
Acute Versus Chronic Hyponatremia
A Practical Approach to Hyponatremia Management:
Conventional and Novel Therapies
Learning Objective
� Describe appropriate pharmacologic strategies for managing hyponatremia
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
17
Treatment Overview
� Most important treatment factors� Severity of neurologic symptoms1,2
� Volume status1,2
� Acute vs chronic2,3
� Identify likely cause of hyponatremia1
� Principles to guide treatment� Weigh risks and benefits4
� Neurologic consequences can follow both failure to promptly treat and excessively rapid rate of correction3
� Even modest improvement in serum [Na+] have survival benefits5
� Monitor serum [Na+] frequently2,6
� Address underlying disease and stop offending medications1
311. Ellison DH et al. N Engl J Med. 2007;356:2064-2072. 2. Lien YH et al. Am J Med. 2007;120:653-658. 3. Ghali K. Cardiology.
2008;111:147-157. 4. Adrogue HJ et al. N Engl J Med. 2000;342:1581-1589. 5. Rossi J et al. Acute Card Care. 2007;9:82-86.
6. Vaidya C et al. Cleve Clin J Med. 2010;77(10):715-726.
Correct Serum [Na+] to Safe Level at Safe Rate
Insufficient correction1
Cerebral edema ODS
Too aggressive correction1
32
� Raise [Na+] by <8–12 mEq/L in 1st 24 h1-3
� Raise [Na+] by <18 mEq/L in 1st 48 h1
� Symptomatic: 1 mEq/L/h until neurologic symptoms resolve or [Na+] ≥120 mEq/L or a total magnitude correction of 18 mEq/L is achieved1,2
1. Verbalis JG et al. Am J Med. 2007;120:S1-S21. 2. Kumar S et al. In: Atlas of Diseases of the Kidney. 1999:1.1-1.21.
3. Adrogue HJ et al. N Engl J Med. 2000;342:1581-1589.
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
18
Risks of Hyponatremia & Correction: A Balancing Act
Acute hyponatremia
Marked brain edema
Minimal brain volume
regulation
Chronic symptomatic hyponatremia
Some brain edema
Partial brain volume
regulation
Chronic asymptomatic hyponatremia
Minimal brain edema
Complete brain volume
regulation
Verbalis JG. Trends Endocrinol Metab. 1992;3(1):1-7.
Risks of
hyponatremia
Risks of
correction
33
Serum [Na+] =Na+
E + K+E
Body water
2. Subtract from
the denominator
1. Add to the
numerator
Na+E, exchangeable sodium; K+
E, exchangeable potassium.
Adrogue HJ et al. N Engl J Med. 2000;342:1581-1589. 34
Correcting Hyponatremia
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
19
Case StudyReview
80-year-old woman with multiple medical problems including HF, HTN, GERD, COPD
� She has chronic hyponatremia (current [Na+] 121 mEq/L) and symptoms consistent with this diagnosis
� She has had a poor response to fluid restriction and a loop diuretic (furosemide)
� No evidence of fluid overload at this time
35
Case StudyEtiology
What is the most likely etiology of this patient’s hyponatremia?
A. Heart failure
B. Drug-induced (SSRI)
C. Pulmonary disease
D. Drug-induced (diuretic)
36
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
20
Case StudyNext Steps
What are the treatment considerations?
What are the treatment options?
A. Hypertonic saline infusion
B. Addition of NaCl tablets
C. AVP receptor antagonist
D. Fluid restriction to <1 L/d
37
Treatments for Hyponatremia
1. Goldsmith SR. Am J Cardiol. 2005;95(suppl):14B-23B. 2. Verbalis JG. Endocrinol Nutr. 2010;57(suppl 2):30-40. 3. Kumar S et al. In: Schrier RW et al (eds). Atlas of Diseases of the Kidney. Vol. 1. Philadelphia, PA: Current Medicine, Inc; 1999:1.1-1.22. 4. Rosner MH. Kidney Int. 2012;82(11):1154-1156. 5. Decaux G et al. Lancet. 2008;371:1624-1632. 38
Treatment1,2 Benefits Limitations
Saline infusion
• Rapid response in
symptomatic patients1
• Complex calculations1
• Not be used in edema-forming
disorders2
Fluid restriction• Inexpensive3 • Slow and limited response1,4
• Adherence concerns1,3
Demeclocycline
• No need to limit water intake3
• Targets excessive AVP1
• Slow response1,4
• Nephrotoxic in CHF and
cirrhosis1,3,4
Loop diuretics• Allows relaxation of fluid
restriction4
• May cause volume, K+ , + Mg+
depletion1
AVP receptor
antagonists
• Target excessive AVP4
• Aquaresis (solute-free urine
output)1,3
• Not to be used in hypovolemic
states5
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
21
The Role of Hypertonic Saline (HTS)
� Consider HTS (3% NaCl) when� Symptomatic hyponatremia (seizure, coma)1
� Acute severe hyponatremia (<24 h, <120 mEq/L)2
� Hyponatremia worsening on normal saline (0.9% NaCl) 3
� Induced hypernatremic states for prevention/treatment of cerebral edema4
� Discontinue HTS when serum [Na+] reaches 125–130 mEq/L3
� Exception: states of cerebral edema with Na+ augmentation
� Safety concerns: requires ICU monitoring2
� Adrogué-Madias formula, used to predict rise in [Na+] after HTS, may underestimate correction rate, increasing risk for inadvertent overcorrection1
� No randomized trials performed1
� HTS may or may not be combined with loop diuretic1
1. Zietse R et al. NDT Plus. 2009;2(Suppl 3): iii12–iii19. 2. Verbalis JG. Endocrinol Nutr. 2010;57(Supl. 2):30-40. 3. Adrogue HJ et al. N Engl J Med. 2000;342:1581-1589. 4. Murphy N et al. Hepatology. 2004;39(2):464-470. 39
Fluid Restriction
� Standard procedure: restrict fluid to <1 L/d1
� Slow rate of improvement2
� Poor patient adherence2
� Predictors of failure3
� High Uosm (>500 mOsm/kg H2O)
� Urine [Na+] and [K+] > serum [Na+]
� 24-h urine output <1,500 mL/d
� Increase in serum [Na+] <2 mEq/L in 24 h
� Not appropriate for hypovolemic hyponatremia4
40Uosm, urine osmolality.1. Goldsmith SR. Am J Cardiol. 2005;95(suppl):14B-23B. 2. Rosner MH. Kidney Int. 2012;82:1154–1156.3. Courtesy of Joseph G. Verbalis, MD. 4. Adrogue HJ et al. N Engl J Med. 2000;342:1581-1589.
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
22
Demeclocycline
� Causes nephrogenic form of diabetes insipidus, decreasing urine concentration even in presence of high plasma AVP levels
� Dose: 600 to 1,200 mg/d in divided doses� Takes several days to achieve maximal diuretic effects
� Wait 3–4 d before deciding to increase dose
� Can cause � Reversible azotemia
� Nephrotoxicity (especially in patients with cirrhosis)
� Monitor renal function on regular basis, discontinue if increasing azotemia
41Verbalis JG et al. Am J Med. 2007;120(11A):S1-S21.
Loop Diuretics
� Increase rate of urine flow, excretion of Na+ and Cl-1
� Allow relaxation of fluid restriction2
� Can be used in SIADH patients when fluid restriction alone is insufficient, taking care to avoid hypovolemiafrom diuretic-induced sodium losses3
� Can enhance free water excretion and help prevent volume overload in patients being treated with HTS for acute symptomatic hyponatremia4
� Potential for volume depletion, K+ and Mg2+ depletion, ototoxicity1,5
421. Goldsmith SR. Am J Cardiol. 2005;95(suppl):14B-23B. 2. Rosner MH. Kidney Int. 2012;82:1154–1156. 3. Goh KP et al. Am Fam
Physician. 2004;69:2387-2394. 4. Lauriat SM et al. J Am Soc Nephrol. 1997;8(10):1599-1607. 5. Kumar S et al. In: Schrier RW et al (eds). Atlas of Diseases of the Kidney. Vol. 1. Philadelphia, PA: Current Medicine, Inc; 1999:1.1-1.22.
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
23
The Vaptans: Overview
1. Decaux G et al. Lancet. 2008;371:1624-1632. 2. Hline SS et al. Ther Clin Risk Manag. 2008;4(2):315-326. 3. Verbalis JG. Cleve Clin J
Med. 2006;73(Suppl 3):S24-S33. 4. Zietse R et al. NDT Plus. 2009; 2(Suppl 3):iii12-19. 5. Ross E, Sigal SH. J Hosp Med. 2010;5(6):S8-S17.
6. Zmily HD et al. Int J Nephrol Renovas Dis. 2011;4:57-71. 7. Samsca (tolvaptan)[prescribing information]. Rockville, MD: Otsuka
America Pharmaceutical, Inc.; April 2013. 8. Lixivaptan. www.drugs.com/nda/lixivaptan_120913.htm. Accessed April 30, 2013. 43
Agent
Receptor
Selectivity/
Affinity Route
t1/2,
h
Urine
Volume
Urine
Osmolality FDA Status
Therapy
Duration
Conivaptan
Mixed (V1A+V2);1
V2 affinity 10××××that of V1A
2
IV1 3–81,2 ↑↑↑↑3,4 ↓↓↓↓3,4Approved
20055 4 d1
Tolvaptan
Selective for V2;3,4
V2 affinity 1.8××××native AVP;
V2 affinity 29××××that of V1A
Oral1 6–121,6 ↑↑↑↑3,4 ↓↓↓↓3,4Approved
20095 <30 d7
Lixivaptan V23,4 Oral1 7–101 ↑↑↑↑3,4 ↓↓↓↓3,4
Additional
data
requested8
NA
The Vaptans: Mechanism of Action
© Leiden University. From Dubois EA et al. Br J Clin Pharmacol. 2012;73(1):9-11.
� Vaptans block effects of AVP in the kidney
� This results in fewer AQP2
channels in the apical membrane
� Fewer water molecules are retained and more water is excreted in urine
� Posm eventually increases and normal plasma [Na+] achieved
44
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
24
Conivaptan Clinical Studies
� Double-blind, placebo-controlled, randomized, multicenter study of 84 patients with euvolemic/hypervolemic hyponatremia (serum [Na+] 115 to <130 mEq/L); all received fluid restriction ≤2 L/d1
� Conivaptan administered 20 mg loading dose (over 30 m) with 4-d continuous infusion of either 40 mg/d or 80 mg/d
� Mean increase in serum [Na+]from baseline significantly higher with conivaptan vs placeboat 24, 48, 72 h posttreatment
Conivaptan 80 mg: 8.1–8.8 mEq/L
Conivaptan 40 mg: 6.4–6.9 mEq/L
Placebo: 0.4–1.9 mEq/L
451. From Zeltser D et al. Am J Nephrol. 2007;27:447-457.
Reproduced with permission of S./KARGER AG in the format reuse in CME materials via Copyright Clearance Center.
Conivaptan Clinical Studies (continued)
� Mean free water clearance from baseline to treatment Days 1 + 2 significantly higher with conivaptan 40 + 80 mg/d than placebo (P<.001, P=.03)1
� Most common AEs: hypotension, postural hypotension, infusion site inflammation, pyrexia, hyperkalemia (no ODS)1
� In an open-label extension trial, mean serum [Na+] was maintained over time2
AE, adverse event. 1. Zeltser D et al. Am J Nephrol. 2007;27:447-457.
2. VAPRISOL (conivaptan hydrochloride injection)
[prescribing information]. Deerfield, Ill: Astellas
Pharma US, Inc.; October 2012. 46120
125
130
135
140
Baseline Day 11 Day 34
Mean
seru
m [
Na+
], m
Eq
/L
Conivaptan 20 mg/d (n=37)
Conivaptan 40 mg/d (n=214)
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
25
Tolvaptan Clinical Studies(SALT-1, SALT-2, SALTWATER)
� 2 double-blind, randomized, multicenter studies of 448 patients with euvolemic or hypervolemic hyponatremia (serum [Na+] <135 mEq/L) treated with placebo or tolvaptan, 15 mg/d
� For first 4 d, dose could be increased from 15–30 mg or from 30–60 mg
� If serum [Na+] rose above 145 mEq/L or increased too fast (>12 mEq/L in 24 h or >8 mEq/L in 8 h on Day 1), the next dose was withheld or decreased, or fluid intake was increased
� Serum [Na+] increased more in tolvaptan group than in placebo group during first 4 d (P<0.001) and after full 30 d of therapy (P<0.001)
47Schrier RW et al.
N Engl J Med. 2006;
355:2099-2112.
SALT-1 SALT-2
Tolvaptan Placebo Tolvaptan Placebo
Baseline 128.5 ± 4.5 128.7 ± 4.1 129.0 ± 3.5 128.9 ± 4.5
Day 4 133.9 ± 4.8 129.7 ± 4.9 135.3 ± 3.6 129.6 ± 5.2
Day 30 135.7 ± 5.0 131.0 ± 6.2 135.9 ± 5.9 131.5 ± 5.7
Tolvaptan Clinical Studies (SALT-1, SALT-2, SALTWATER continued)
� Increase in serum [Na+] in tolvaptan group sustained 30 d1
� Most common AEs: thirst, dry mouth, polyuria (no ODS)1
� In an open-label study, increases in serum [Na+] were significant and maintained over the long term (mean follow up 701 d)2
481. Schrier RW et al. N Engl J Med. 2006;355:2099-2112. 2. Advisory Committee Meeting of the Cardiovascular and Renal Drugs Division
of the US FDA. June 25, 2008. Available at: www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4373b1-05.pdf. Accessed March 15, 2013.
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
26
SIADH Cost Analysis
� Cost estimate methods
� HCUP 2009 Nationwide Inpatient Sample database� 21,718 patients hospitalized for SIADH: mean LOS 5.7 d, mean hospital cost $8667
� Used tolvaptan treatment duration of 4 d at $250/dose
� LOS reduction estimate based upon SALT-1 and SALT-2 trials� SIADH patients receiving tolvaptan had shorter hospital LOS (4.98 vs 6.19 d)
� Results
� Cost offset model estimated LOS reduction of 1.11 d and total cost offset of $694 per admission� 95% CI for cost offset using Monte Carlo simulation was $73‒$1405
� Cost-neutral break-even mean duration of tolvaptan inpatient use: 6.78 d
� Use of tolvaptan to treat these 21,718 patients identified in the HCUP population would result in total cost offset >$15 million
CI, confidence interval.Dasta JF et al. Hosp Practice. 2012;40(1):1-8. 49
Bioavailability of Tolvaptan Administered via NG Tube
� Tolvaptan 15 mg crushed and administered via NG tube vs oral tablet swallowed intact (each with 240 mL H20)� Randomized crossover study in 28 healthy fasted adults
� Administration with NG tube compared with oral intact tablet� Cmax ≈10% lower and AUCt and AUC
∞≈25% lower
� No evidence of different aquaresis� 24-h urine output 2.8% lower with NG tube
AUC, area under the curve; Cmax,, maximum concentration; NG, nasogastricMcNeely EB et al. Am J Health Syst Pharm. 2013;70:1230-1237.
Relative Bioavailability
Est. Ratio of Geometric Means With NG vs Oral
Administration, % 90% CI
Cmax (ng/mL) 88.9 80.1–98.6
AUCt (ng � h/mL) 74.3 68.1‒81.0
AUC∞ (ng � h/mL) 74.2 68.1–80.9
50
Mean plasma concentration–
time profiles after oral vs
NG tube administration
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
27
The Vaptans: Contraindications & Precautions
Conivaptan/tolvaptan1,2
� Do not use with potent CYP3A and P-glycoprotein inhibitors, or in hypovolemic or anuric patients
� Use with caution in patients with hepatic or renal impairment
� Monitor serum [Na+] and neurologic status
Conivaptan1
� Do not use in patients with known allergy to corn or corn products
� May cause significant infusion site reactions
Tolvaptan2
� Do not use in patients unable to respond appropriately to thirst
� Liver injury noted in study of ADPKD patients (incidence of ALT >3x ULN in 4.4% [42/958] of tolvaptan patients vs 1.0% [5/484] of placebo patients)
� Therefore, limit treatment to 30 d, discontinue treatment if hepatic injury suspected, avoid use in patients with underlying liver disease
51
ADPKD, autosomal dominant polycystic kidney disease; ULN, upper limit of normal.
1. Vaprisol (conivaptan hydrochloride injection)[prescribing information]. Deerfield, Ill: Astellas Pharma US, Inc.; October 2012.
2. Samsca (tolvaptan)[prescribing information]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; April 2013.
The Vaptans: Drug–Drug Interactions
Conivaptan1
� Substrate/inhibitor of CYP3A
� Concomitant use of conivaptan
and potent CYP3A inhibitors
(ketoconazole, itraconazole,
clarithromycin, ritonavir, or
indinavir) is contraindicated
� Generally avoid CYP3A
substrates
� Exposure to coadministered
digoxin may be increased and
digoxin levels should be
monitored
Tolvaptan2
� Substrate of CYP3A
� Concomitant use of tolvaptan and potent CYP3A inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, or indinavir) is contraindicated
� Avoid use with CYP3A inducers and moderate CYP3A inhibitors
� Does not significantly change pharmacokinetics of other CYP3A substrates
� Coadministration with digoxin results in 1.3-fold increase in digoxin Cmax
� Coadministration with P-gp inhibitors may require dose reduction of tolvaptan
521. Vaprisol (conivaptan hydrochloride injection)[prescribing information]. Deerfield, Ill: Astellas Pharma US, Inc.; October 2012.
2. Samsca (tolvaptan)[prescribing information]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; April 2013.
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
28
Monitoring Patients on Conivaptan
� Only for use in hospitalized patients
� Administer through large veins, change infusion site every 24 h to minimize risk of vascular irritation
� Monitor serum [Na+] and neurologic status appropriately, as serious neurologic sequelae can result from overly rapid correction (>12 mEq/L in 24 h)
� Discontinue conivaptan if patient develops undesirably rapid rate of rise of serum [Na+], and carefully monitor serum [Na+]and neurologic status
� If serum [Na+] continues to rise, do not resume treatment
� If hyponatremia persists or recurs, and patient has had no evidence of neurologic sequelae of rapid rise in serum [Na+], conivaptan may be resumed at reduced dose
53Vaprisol (conivaptan hydrochloride injection)[prescribing information]. Deerfield, Ill: Astellas Pharma US, Inc.; October 2012.
Monitoring Patients on Tolvaptan
� Medication MUST be started and re-started in the hospital1
� Obtain serum [Na+] every 4-6 h for 48 h2
� In clinical trials, no patients had evidence of ODS1
� In postmarketing surveillance, cases of ODS have been identified in which HTS was administered concomitantly or in close approximation to tolvaptan1
� As many as 35% of patients (especially those with highest Uosm) may need concomitant water restriction to see rise in serum [Na+]1
� After 48 h, vast majority reach steady state and can be safely discharged with outpatient monitoring2
� Check serum [Na+] once a week for the first month2
� Outpatient administration should be limited to ≤30 d per label.1
If administration is continued, [Na+] should be monitored monthly if stable, and patient should be closely monitored for any signs of liver impairment2
541. Samsca (tolvaptan). [prescribing information]. Rockville, MD. Otsuka America Pharmaceutical, Inc.; April 2013.
2. Faculty recommendations.
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
29
Case StudyTreatment Course
� Patient admitted
� Fluid restriction discontinued
� Tolvaptan therapy initiated at 15 mg/d
� Uptitrated to tolvaptan 30 mg/d after 24 h
55
Case Study Response to Therapy
� Urine volume increased, urine osmolality decreased, and
serum [Na+] increased by 4.5 mEq/L/d over first 48 h
� Patient discharged after 3 d with [Na+] 136 mEq/L
56
121 123126 124
130 132 133 132
100
110
120
130
140
Admission 8 h 16 h 24 h 32 h 40 h 48 h 56 h
Se
rum
[N
a⁺]
,
mE
q/L
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
30
Treatment Algorithm
Fluid restriction; vaptan under select circumstances:
•Inability to tolerate fluid restriction or failure of fluid restriction
•Prevention of worsened hyponatremia with increased fluid administration
•Unstable gait and/or high fracture risk
•Serum [Na+] <125 mEq/L
•To correct serum [Na+] to safer levels for surgery/procedures or ICU/hospital discharge
• Therapeutic trial for symptom relief
Euvolemic
hyponatremia
Verbalis JG et al. Am J Med. 2007;120:S1-S21.
Hypovolemic
hyponatremia
Level 1:
No or
minimal
symptoms
Hypervolemic
hyponatremia
Saline or
HTS
± fludro-cortisone
Level 2:
Moderate
symptoms
Level 3:
Severe
symptoms
Vaptan ±±±± fluid restriction Vaptan ±±±± fluid restriction
HTS followed by
fluid restriction
±±±± vaptan
HTS followed by
fluid restriction
±±±± vaptan����
Vaptan ±±±± fluid
restriction����
57
Top 10 Take-Aways
1. Role of AVP in pathophysiology of SIADH and hypervolemia
2. Hyponatremia has real impacts on costs and outcomes
3. Chronic consequences of hyponatremia
4. When hyponatremia is present, consider drug-related causes
5. Be vigilant for cognitive dysfunction at any level of hyponatremia
6. Treatment algorithm
7. Vaptans are necessary "tool" in the treatment algorithm
8. Rate of serum [Na+] correction important
9. Monitor, monitor, monitor during [Na+] correction for safety
10. Know vaptan AEs, drug interactions
58
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
31
Supplemental Slides
Role of AVP in Edematous Disorders
Adapted from Janicic N et al. Endocrinol Metab Clin North Am. 2003;32:459-481. S1
CHF���� Cardiac output
Cirrhosis���� Peripheral resistance dueto splanchnic vasodilation
Arterial underfilling
Stimulation of arterialbaroreceptors
Nonosmotic release of AVP
Impaired H2O excretion
Hypervolemic hyponatremia
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
32
<100 mOsm/L(maximally dilute)
Polydipsia
≥100 mOsm/L(inappropriately concentrated)
Impaired water excretion
HyperglycemiaMannitol
>295 mOsm/kgHyperosmolar
HypervolemiaIncreased ECF volume
ECF, extracellular fluid.Cole CD et al. Neurosurg Focus. 2004;16:E9. Diringer MN, Zazulia AR. Neurologist. 2006;12(3):117-126.
Schrier RW, ed. Atlas of Diseases of the Kidney. Philadelphia, PA: Current Medicine. 1999:1.1-1.22.
[Na+] <135 mEq/L
<275 mOsm/kgHypo-osmolar
Assess serum osmolality
Assess urine osmolality
Excessive water intake
Assess volume status
EuvolemiaNormal ECF volume
HypovolemiaReduced ECF volume
275-295 mOsm/kgNormo-osmolar
PseudohyponatremiaNa-free irrigant solutions
S2
Classification Algorithm
� Caused by excessive levels of AVP as a result of disease, drug-induced pituitary release of AVP, or ectopic production of AVP
� AVP secretion not suppressed appropriately when Posmfalls below the osmotic threshold1,2
� The inability to suppress AVP secretion results in
� Impaired renal water excretion
� Increased total body water
� Hyponatremia
� “Dilute serum, nondilute urine”
SIADH: Pathophysiology
1. Verbalis JG. J Mol Endocrinol. 2002;29:1-9. 2. Robertson GL et al. Am J Med. 1982;72:339-353. S3
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
33
� ↓↓↓↓ Effective osmolality of the ECF (Posm <275 mOsm/kg H2O)
� Inappropriate urinary concentration (Uosm >100 mOsm/kg H2O) with normal renal function at some level of hypo-osmolality)
� Clinical euvolemia (no signs of hypovolemia or hypervolemia)
� Elevated urinary Na excretion despite normal salt and H2O intake
� No other potential causes of euvolemic hypo-osmolality
Essential Criteria for Diagnosis of SIADH
Posm, plasma osmolality; Uosm, urinary osmolality.
Janicic N, Verbalis JG. Endocrinol Metab Clin North Am. 2003;32(2):459-481. S4
Most Common Diagnoses in Hospitalized Patients With Hyponatremia
S5Zilberberg MD et al. Curr Med Res Opin. 2008; 24(6):1601-1608.
DiagnosisHyponatremia
Incidence
Pneumonia, organism unspecified 6.0%
Septicemia 5.5%
Disorders of fluid, electrolyte, and acid–base balance (including hyponatremia)
5.3%
Heart failure 5.3%
Diabetes mellitus 5.0%
Acute renal failure 3.9%
Acute myocardial infarction 3.2%
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
34
� Direct costs estimated at $1.6 to $3.6 billion annually1
� Hospitalization costs account for ≈70% of total cost of illness
� Associated with worse clinical and economic outcomes2
� Patients with hyponatremia have
� 10% to 32% increased risk of requiring ICU stay2,3
� Adjusted mean LOS of 3.06 d longer4
� Adjusted OR of 1.64 for requiring discharge to short- or long-term care facility5
� 41.2% higher cost at 6 mo; 45.7% higher at 1 y6
Costs of Hyponatremia
1. Boscoe A et al. Cost Eff Resour Alloc. 2006;4:1-11. 2. Zilberberg MD et al. BMC Pul Med. 2008;8:16. 3. Callahan MA et al.
Postgrad Med. 2009;121(2):186-191. 4. Cyr PL et al. Am J Health Syst Pharm. 2011;15(68(4):328-333. 5. Wald R et al. Arch Intern Med.
2010;170:294-3024. 6. Shea AM et al. J Am Soc Nephrol. 2008;19:764-770. S6
Moderate-Severe (≤129
mEq/L)
32% ICU admission
Total costs*
$19,519
8-d LOS
Costs of Admission Hyponatremia (adjusted for clinical & demographic variables)
*Per admission.
Callahan MA et al. Postgrad Med. 2009;121(2):186-191.
Mild-Moderate (130–134 mEq/L)
26% ICU admission
8-d LOS
Total costs*
$18,054
Normal
(135–145 mEq/L)
22% ICU admission
6-d LOS
Total costs*
$17,085
Difference = $2434
Difference = $969
S7
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
35
� Retrospective study in 77 medical, surgical, and mixed ICUs in Austria
� 151,486 adults admitted consecutively over 10 y (1998–2007)
� Borderline (130 ≤ [Na+] <135 mEq/L) hyponatremia: 13.8%
� Mild hyponatremia (125 ≤ [Na+] <130 mEq/L): 2.7%
� Severe hyponatremia ([Na+] <125 mEq/L): 1.2%
� Independent mortality risk with increasing severity of hyponatremia
� Borderline: OR, 1.32 (95% CI, 1.25–1.39)
� Mild: OR, 1.89 (95% CI, 1.71–2.09)
� Severe: OR, 1.81 (95% CI, 1.56–2.10)
Hyponatremia Associated with Increased Mortality in Patients in the ICU
Funk GC et al. Intensive Care Med. 2010;36(2):304-311. S8
Change in Serum [Na+] & Mortality
Waikar SS et al. Am J Med. 2009;122:857-865. S9
0
10
20
30
40
50
In-hospital 1-y 5-y
Crude Mortality, %Normonatremia
Resolution of
Hyponatremia
Persistent
Hyponatremia
Acquired
Hyponatremia
Adjusted HR for Mortality
In-hospital 1-y 5-y
Normonatremia (n=42176) 1 (ref) 1 (ref) 1 (ref)
Resolution of hyponatremia (n=3794) 1.26 1.19 1.18
Persistent hyponatremia (n=4524) 2.37 1.55 1.32
Acquired hyponatremia (n=1974) 2.44 1.54 1.40
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
36
Whyte M et al. Int J Clin Pract. 2009;63:1451-1455.
� 113 patients with severe hyponatremia (serum [Na+] ≤120 mEq/L)
� Relationship between investigation for hyponatremia and mortality
Failure to Measure Plasma & Urinary Osmolalities Associated With Increased Hyponatremia Mortality
S10
14.3 12.79.8
32 3430
0
10
20
30
40
Serum Osmolality Urine Osmolality Paired Osmolality
Mortality, %
Measured
Not measured
� 115,969 patients hospitalized for CHF
� Grouped by serum [Na+]Eq/L
Impact of Hyponatremia on Cost in Hospitalized Patients With HF
Shorr AF et al. Congest Heart Fail. 2011;17(1):1-7. S11
Serum [Na+],
mEq/L
Risk-Adjusted
Attributable Hospital Cost
Hypernatremia >145 $99
Normonatremia (ref) 136–145 0
Hyponatremia 131–135 $509
Severe hyponatremia ≤ 130 $1132
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
37
� 15 randomized, controlled trials of vaptans with or w/o fluid restriction
� Primary result: Normal or significant increase in serum [Na+] at 3-7 d
� Vaptan treatment significantly increased
� Early response rate (11 trials): RR, 3.15; 95% CI, 2.27–4.37
� Late response rate (4 trials): RR, 2.27; 95% CI 1.79–2.89
� Rates of hypernatremia (5 trials): RR, 2.21; 95% CI, 0.61–7.96
� No cases of ODS
Meta-analysis: Vaptans for Hyponatremia
Rozen-Zvi B et al. Am J Kidney Dis. 2010;56(2):325-337. S12
� Objectives of this post-hoc analysis of EVEREST trial � Compare LOS between normonatremic (n=1789) and
hyponatremic (n=216) patients who were randomized to placebo
� Evaluate the effect of tolvaptan (n=225) compared with placebo (n=216) on LOS in hyponatremic patients
� LOS in hyponatremic vs normonatremic patients � Serum [Na+] <135 mEq/L: LOS + 3.06 d (P<.001)
� More severe hyponatremia: LOS + 5.17 d (P<.001)
� LOS tolvaptan vs placebo� 1.72 d shorter vs placebo (P=NS)
� 2.12 d shorter in patients with more severe hyponatremia (P=NS)
Effect of Serum [Na+] & Tolvaptanon LOS in Hospitalized Patients With HF
Cyr PL et al. Am J Health Syst Pharm. 2011;68(4):328-333. S13
Hyponatremia: Obstacles and Opportunities for Clinical Pharmacists
© 2013 Paradigm Medical Communications, LLC, except where noted.
38
S14
Pro
po
rtio
n W
ith
ou
t E
ven
t
Post-hoc Exploratory Analysis EVEREST: CV Mortality & Morbidity
Advisory Committee Meeting of the Cardiovascular and Renal Drugs Division of the US Food and Drug Administration. June 25,
2008. Available at: www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4373b1-05.pdf. Accessed March 15, 2013.
� Hospital cost and LOS for DRG hospitalizations of adult HF patients with
complications, comorbidities estimated from HCUP 2008 NIS database
� Reductions in LOS associated with tolvaptan estimated from EVEREST
trial data for hyponatremic patients
� Cost offset model used to evaluate impact of tolvaptan on LOS and
hospital cost
� LOS reduced 0.81 d among HF hospitalizations
� $265 total cost savings per admission (based on wholesale acquisition cost
of $250/d)
� Supports clinical and economic benefit of tolvaptan use
� Study limitation: Clinical trial patient profiles and relative LOS
reductions may not be applicable to real-world patient populations
Economic Benefits of Tolvaptanin Hyponatremic HF Patients
DRG, diagnosis-related group; HCUP, Healthcare Cost and Utilization Project; NIS, Nationwide Inpatient Sample.
Chiong JR et al. J Med Econ. 2012;15(2):1-9. S15